News Center

Company news

Media reports

06

2021-07

Kintor: Q2 2021 Business Update at a Glance

Kintor: Q2 2021 Business Update at a Glance

Picture Name

15

2021-06

Proxalutamide's Pivotal Study of Treating COVID-19 Male Outpatients Sponsored by Kintor was Approved by ANVISA and CONEP in Brazil

Suzhou, June 15, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the Brazilian Health Regulatory Agency (ANVISA) has approved the phase III clinical trial of proxalutamide to treat male patients with mild or moderate COVID-19 symptoms on June 11, 2021[1].

Picture Name

18

2021-05

Kintor Announces (1) FDA Has Greenlighted Proxalutamide’s Phase III Study for Hospitalised Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide’s Phase III Study for Mild to Moderate COVID-19

Suzhou, May 18, 2021 - Kintor Pharmaceutical Limited (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's phase III clinical trial of hospitalised COVID-19 patients to be conducted, which will recruit both male and female patients. Separately, the FDA agreed to the addition of female patients to its ongoing proxalutamide phase III clinical trial in outpatients with mild to moderate COVID-19 illness. The company will publish and update details of these pivotal studies at ClinicalTrials.gov.

Picture Name

16

2021-05

Kintor Appointed Dr. Qun Lu as CTO and Dr. Jiawen Han as BD VP

Suzhou, China, May 16, 2021 —Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the appointment of Dr. Qun Lu as the Chief Technology Officer (CTO) and Dr. Jiawen Han as vice president of business development. Dr. Lu will be primarily responsible for Chemistry, Manufacturing, and Control (the “CMC”) including drug analysis, formulation development and the production. Dr. Han will be primarily responsible for business development-related projects and management. Both of Dr. Lu and Dr. Han will be reporting to Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharmaceuticals.

Picture Name

30

2021-04

Kintor Has Expanded Its Geographical Presence to Zhuhai

Zhuhai, China, Apr.30, 2021--Kintor Pharmaceutical Limited announced today that the company has expanded geographical presence to Zhuhai, Guangdong Province (“Zhuhai office”).

Picture Name

25

2021-04

Kintor Pharmaceuticals Announced Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S.

Suzhou, China, April.25, 2021 — Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the phase III clinical trial of proxalutamide for the treatment of male patients with mild or moderate COVID-19 symptoms in the United States has completed the first patient enrollment and dosing.

Picture Name
< 1...151617...25 > proceed page

Kintor